GlaxoSmithKline (GSK) has launched a new $5m fund, dubbed Innovation Challenge Fund, targeting the bioelectronics sector.
Academics and spin-outs are set to profit from the fund, which GSK is hoping will advance research and development of small implantable devices as therapeutics, as opposed to the traditional pills and injections.
According to a statement, GSK is hoping the fund will lead to the creation of implants which can be programmed “to read and correct the electrical signals that pass along the…
